Business Update Positive

2026-11-05 09:52

Dr. Reddy's Laboratories received marketing authorization from ANVISA for generic semaglutide injection in Brazil for treating type 2 diabetes mellitus. - The product will be available in 2 mg/1.5 mL and 4 mg/3 mL pre-filled pens. - The company plans to launch the product in Brazil in partnership with Aché.

Business Update Positive

2026-11-05 09:48

Dr. Reddy's Laboratories received marketing authorization from ANVISA (Brazil) for generic semaglutide injection for type 2 diabetes mellitus. - The approval covers pre-filled multi-dose injectable pens in 2 mg/1.5 mL and 4 mg/3 mL strengths for once-weekly dosing. - The semaglutide diabetes market in Brazil is estimated at approximately USD 244.6 million. - The company plans to commercialize the product in partnership with Aché.

Governance Neutral

2026-11-04 12:07

- Dr. Reddy's Laboratories has allotted 5,91,270 equity shares of Re. 1/- each on November 4, 2026. - Shares were issued pursuant to the exercise of stock options under the Dr. Reddy’s Employees ADR Stock Options Scheme, 2007. - Total issued share capital stands at Rs. 83,52,72,555/- following this allotment.

Governance Neutral

2026-11-04 12:05

- Dr. Reddy's Laboratories has allotted 5,91,270 equity shares of face value Re. 1/- each on November 4, 2026, pursuant to the exercise of stock options under the Dr. Reddy's Employees ADR Stock Options Scheme, 2007. - The total issued share capital after this issue stands at Rs. 83,52,72,555/-.

Business Update Positive

2026-11-04 11:48

- Dr. Reddy's Laboratories clarified that the media report regarding US FDA approval for its generic HIV prevention shot is correct. - The company confirmed it received tentative US FDA approval for twice-yearly injectable lenacapavir for 120 countries. - The company stated this event was based on its earlier press release.

Business Update Positive

2026-11-04 11:39

- Dr. Reddy's Laboratories clarified a news article regarding US FDA tentative approval for its twice-yearly injectable lenacapavir for HIV prevention. - The company confirmed the headline is correct, noting it pertains to their press release dated November 2, 2026. - The company stated there is no material impact of the article on the company and no undisclosed material information.

Business Update Neutral

2026-10-29 22:57

Dr. Reddy's Laboratories Limited has submitted the transcript of the earnings call conducted on October 23, 2026, for the quarter and half year ended September 30, 2026. - The transcript is available on the company website.

Business Update Neutral

2026-10-29 22:55

Dr Reddy's Laboratories Ltd has submitted the transcript of the earnings call conducted on October 23, 2026, for the quarter and half year ended September 30, 2026. - The transcript has been made available on the company website.

Routine Neutral

2026-10-28 18:40

New Filing detected. See link for details.

Business Update Positive

2026-10-28 18:30

- USFDA classified the inspection outcome for FTO-SEZ Process Unit-02 at Srikakulam as 'Voluntary Action Indicated (VAI)'. - The inspection has been officially closed by the USFDA.

Business Update Neutral

2026-10-24 11:24

Concall Schedule Concall Date: October 23, 2026 Audio and video recording links provided for the earnings call on financial results for the quarter and half year ended September 30, 2026.

Business Update Neutral

2026-10-24 11:13

- The company submitted audio and video recordings of the earnings call held on October 23, 2026. - The call was conducted to discuss the unaudited financial results for the quarter and half year ended September 30, 2026. - The submission was made pursuant to Regulation 30 of SEBI LODR Regulations.

Routine Neutral

2026-10-23 22:34

- Submission of Limited Review Reports of Statutory Auditors bearing UDIN. - Pertains to unaudited financial results for the quarter and half year ended September 30, 2026. - Filed as a follow-up to the earlier financial results intimation on October 23, 2026.

Routine Neutral

2026-10-23 22:22

- Dr. Reddy's Laboratories Limited has submitted a general update filing to the Exchange. - No specific material events, financial data, or critical disclosures were provided in the filing.

Governance Neutral

2026-10-23 18:48

- Dr. Reddy's Laboratories has appointed Mr. Akhil Ravi as Head API and Services and Senior Management Personnel, effective November 13, 2026. - He is also inducted as a Member of the Management Council and continues to manage Aurigene Pharmaceutical Services Ltd. - Mr. Akhil Ravi is related to the company as the son-in-law of Mr. G V Prasad, Co-Chairman and Managing Director.

Governance Neutral

2026-10-23 18:46

- Appointment of Mr. Akhil Ravi as Head API and Services and Senior Management Personnel of the company effective November 13, 2026. - Mr. Akhil Ravi is a related party, being the son-in-law of Mr. G V Prasad, Co-Chairman and Managing Director. - He will continue to be responsible for the operations of Aurigene Pharmaceutical Services Ltd., a wholly owned subsidiary.

Financials Neutral

2026-10-23 18:42

Q2 FY27 Consolidated Revenue ₹8,671 Cr vs ₹8,805 Cr (▼2% YoY) EBITDA ₹1,783 Cr vs ₹2,351 Cr (▼24% YoY) PAT ₹925 Cr vs ₹1,437 Cr (▼36% YoY) EBITDA Margin 20.6% vs 26.7% (▼610bps)

Financials Neutral

2026-10-23 18:41

Q2 FY27 Consolidated Revenue ₹8,671 Cr vs ₹8,805 Cr (▼1.5% YoY) EBITDA ₹1,783 Cr vs ₹2,351 Cr (▼24.2% YoY) PAT ₹925 Cr vs ₹1,437 Cr (▼35.6% YoY) EBITDA Margin 20.6% vs 26.7% (▼610bps)

Business Update Neutral

2026-10-23 17:39

- Q2 FY27 consolidated revenue stood at ₹8,671 Cr, down 1.5% YoY due to lower lenalidomide sales. - EBITDA stood at ₹1,783 Cr (20.6% margin), declining 24% YoY. - PAT reached ₹925 Cr, down 36% YoY. - Net cash surplus stood at ₹2,502 Cr with double-digit underlying base business growth.

Business Update Neutral

2026-10-23 17:37

- Q2 FY27 Revenues reported at ₹8,671 Cr, down 1.5% YoY due to lower lenalidomide sales. - EBITDA stood at ₹1,783 Cr (margin at 20.6%), down 24% YoY. - PAT reached ₹925 Cr, down 36% YoY. - Net cash surplus stood at ₹2,502 Cr as of September 30, 2026.

Financials Neutral

2026-10-23 17:34

- Dr. Reddy's Laboratories Board approved unaudited Standalone and Consolidated Financial Results for the quarter and half-year ended September 30, 2026. - Detailed financial figures/tables were not included in the provided document. - The Board Meeting concluded at 4:38 p.m. IST on October 23, 2026.

Financials Neutral

2026-10-23 17:32

- Board approved Unaudited Consolidated and Standalone Financial Results for Q2 and H1 ended September 30, 2026. - Approved results prepared under both IFRS and Ind AS along with Limited Review Reports. - Board meeting concluded at 4:38 p.m. IST on October 23, 2026.

Business Update Positive

2026-10-21 09:45

- Dr. Reddy's Laboratories received DCGI approval for Zytorvi (toripalimab) in combination with chemotherapy for advanced esophageal squamous cell carcinoma (ESCC). - This marks the second approved indication for Zytorvi in India, expanding its use beyond nasopharyngeal carcinoma. - The approval is backed by the Phase 3 JUPITER-06 trial showing improved overall survival and reduced risk of disease or death.

Business Update Positive

2026-10-21 09:40

Dr. Reddy's Laboratories received DCGI approval for Zytorvi (toripalimab) for advanced esophageal squamous cell carcinoma (ESCC) in India. This marks the second approved indication for Zytorvi in India, expanding its use beyond nasopharyngeal carcinoma. The approval is based on Phase 3 JUPITER-06 trial results showing improved overall survival and reduced risk of disease progression.

Business Update Neutral

2026-10-14 20:24

- USFDA completed a Pre-Approval Inspection at the FTO-9 manufacturing facility in Visakhapatnam. - The inspection took place from October 8 to October 9, 2026. - Form 483 was issued with three observations, which the company will address within the stipulated timeline.

Business Update Neutral

2026-10-14 20:20

- USFDA completed a Pre-Approval Inspection at the FTO-9 manufacturing facility in Visakhapatnam from October 8 to October 9, 2026. - The inspection resulted in the issuance of a Form 483 with three observations. - The company will address the observations within the stipulated timeline.

Business Update Neutral

2026-10-08 15:59

- USFDA completed a Pre-Approval Inspection at the FTO-11 manufacturing facility in Pydibhimavaram, Andhra Pradesh from October 5 to October 7, 2026. - The inspection resulted in the issuance of a Form 483 with two observations. - The company will address the observations within the stipulated timeline.

Business Update Neutral

2026-10-08 15:58

- USFDA completed a Pre-Approval Inspection at the FTO-11 manufacturing facility in Pydibhimavaram, Andhra Pradesh. - The inspection took place from October 5, 2026 to October 7, 2026. - Form 483 was issued with two observations, which the company will address within the stipulated timeline.

Business Update Neutral

2026-10-07 14:41

Concall Schedule Concall Date: October 23, 2026 Concall Time: 19:30 PM IST / 10:00 AM ET

Business Update Neutral

2026-10-07 14:40

Concall Schedule Concall Date: Friday, October 23rd, 2026 Concall Time: 19:30 PM IST / 10:00 AM ET

Routine Neutral

2026-10-03 17:17

- Dr. Reddy's Laboratories, Inc. (step-down subsidiary) received a penalty of $32,350.20 from the US IRS. - Penalty imposed due to misclassification of Fiscal year reference at the time of tax payment. - The company confirmed there is no material impact on financials or operations.

Routine Neutral

2026-10-03 17:11

- Dr. Reddy's Laboratories, Inc. received a penalty transcript of $32,350.20 from the US IRS on October 2, 2026. - The penalty was levied due to a misclassification of the fiscal year reference during tax payment. - The company stated there is no material impact on the financials or operations.

Governance Neutral

2026-09-22 17:04

- A Board meeting will be held on Friday, October 23, 2026, to consider and approve the Unaudited Standalone and Consolidated Financial Results for the quarter ended September 30, 2026. - The trading window for dealing in securities of the Company will be closed from September 24, 2026 to October 25, 2026.

Governance Neutral

2026-09-22 17:01

- Board meeting on October 23, 2026, to approve unaudited standalone and consolidated financial results for the quarter ended September 30, 2026. - Trading window for dealing in company securities will be closed from September 24, 2026, to October 25, 2026.

Governance Neutral

2026-09-22 17:00

- Board meeting on October 23, 2026, to consider and approve the unaudited standalone and consolidated financial results for the quarter ended September 30, 2026. - The trading window for dealing in securities will be closed from September 24, 2026, to October 25, 2026.

Business Update Neutral

2026-09-21 16:51

- Concall/Investor Meeting Schedule - Concall Date: September 25, 2026 - Concall Time: 11:00 - 14:00 IST

Business Update Neutral

2026-09-21 16:51

- Investor Meeting Schedule - Meeting Date: September 25, 2026 - Meeting Time: 11:00 - 14:00 IST - Organized by: Nomura - Location: Hyderabad

Business Update Positive

2026-09-18 09:05

- Dr. Reddy's Laboratories Ltd. entered into an exclusive distribution and marketing agreement with Takeda Biopharmaceuticals India Private Limited for Qdenga®. - Qdenga® is India's first CDSCO approved dengue vaccine, providing protection against all four dengue virus serotypes. - Dr. Reddy's will be exclusively responsible for distribution and marketing of Qdenga® in the private market in India. - The vaccine is anticipated to be available in the first half of 2027. - This partnership strengthens Dr. Reddy's vaccine business and aims to address the significant burden of dengue in India. - No upfront consideration or milestone payment was involved; other commercial terms are confidential.

Business Update Positive

2026-09-18 09:02

- Dr. Reddy's entered an exclusive agreement with Takeda for distribution and marketing of Qdenga®, India's first CDSCO approved dengue vaccine, in India's private market. - Availability anticipated H1 2027, strengthening Dr. Reddy's vaccine business and addressing public health.

Business Update Positive

2026-09-18 08:46

- Dr. Reddy's confirmed a voluntary licensing agreement with Gilead Sciences for Gilead's investigational once-yearly HIV prevention drug (lenacapavir). - This expands their collaboration. - The company clarified it does not constitute a material event requiring further disclosure under Regulation 30.

Business Update Positive

2026-09-18 08:42

- Dr. Reddy's Laboratories confirmed a news item regarding a voluntary licensing agreement with Gilead Sciences for investigational once-yearly lenacapavir for HIV prevention. - This agreement expands the company's collaboration with Gilead Sciences.

Business Update Negative

2026-09-11 22:12

CRITICAL RED FLAG DETECTED

- USFDA completed a records assessment at Dr. Reddy's API facility in Mexico from July 17 to September 8, 2026. - The assessment concluded with two observations in Form FDA 2953. - The company will respond to the observations.

Business Update Negative

2026-09-11 22:10

CRITICAL RED FLAG DETECTED

- Dr. Reddy's API manufacturing facility in Jiutepec, Mexico, underwent a USFDA records assessment from July 17 to September 8, 2026. - At the conclusion, the USFDA issued a Form FDA 2953 containing two observations. - The company will respond within the stipulated timeline.

Ownership Neutral

2026-09-10 17:42

- Dr. Reddy's Laboratories Ltd. allotted 375 equity shares of Re. 1/- each on September 10, 2026, to eligible employees under its ESOP scheme. The total issued shares after this allotment are 83,46,81,285.

Business Update Neutral

2026-09-10 17:41

- Investor Meeting Schedule - Meeting on 17.09.2026: Organized by ICICI Securities (Hyderabad, In-Person Group Meet) from 12:30 - 13:30 IST - Meeting on 24.09.2026: Organized by Bank of America (Virtual Group Meet) from 14:00 - 15:00 IST

Ownership Neutral

2026-09-10 17:40

- Dr. Reddy's Laboratories Ltd. allotted 375 equity shares of Re. 1/- each to eligible employees on September 10, 2026. - This allotment was pursuant to the exercise of Stock Options under the Dr. Reddy's Employees ADR Stock Options Scheme, 2007. - Post-allotment, the total issued shares of the Company are 83,46,81,285.

Business Update Neutral

2026-09-10 17:39

- Investor Meetings Schedule: - September 17, 2026: In-person group meeting with ICICI Securities in Hyderabad from 12:30 - 13:30 IST. - September 24, 2026: Virtual group meeting with Bank of America from 14:00 - 15:00 IST.

Routine Neutral

2026-08-26 16:13

- Dr. Reddy's Laboratories Ltd. allotted 4,110 fully paid-up equity shares of Re.1/- each on August 26, 2026. - These shares were allotted to eligible employees under the Dr. Reddy's Employees Stock Options Scheme, 2002.

Ownership Neutral

2026-08-26 15:44

- Dr. Reddy's Laboratories Ltd. allotted 4,110 equity shares (Re.1/- each) on August 26, 2026, to eligible employees under its ESOP Scheme. - Post-allotment, the total issued shares stand at 83,46,80,910.

Business Update Negative

2026-08-14 23:47

CRITICAL RED FLAG DETECTED

- USFDA completed a GMP inspection at Dr. Reddy's FTO-3 formulations manufacturing facility in Bachupally, Hyderabad from August 6-14, 2026. - The company received a Form 483 with four observations, which will be addressed within the stipulated timeline.

Business Update Negative

2026-08-14 23:35

CRITICAL RED FLAG DETECTED

- USFDA completed a GMP inspection at the Bachupally formulations manufacturing facility from August 6-14, 2026. - The company was issued a Form 483 with four observations, which will be addressed within the stipulated timeline.

Business Update Positive

2026-08-14 23:15

- Dr. Reddy's Laboratories announced that the USFDA inspection at its API manufacturing facility in Mirfield, UK, has concluded. - The inspection outcome was classified as 'Voluntary Action Indicated (VAI)', and the inspection is now officially closed.

Business Update Positive

2026-08-14 23:07

- USFDA inspection at Dr. Reddy's Mirfield, UK API manufacturing facility classified as 'Voluntary Action Indicated (VAI)'. - The inspection is now officially closed.

Ownership Positive

2026-08-14 12:14

- ICICI Prudential Mutual Fund acquired 7,12,884 shares of Dr. Reddy's Laboratories Ltd. on August 12, 2026. This increased their total shareholding to 5.037%, exceeding the 5% threshold under SEBI SAST Regulations.

Governance Negative

2026-08-13 16:49

CRITICAL RED FLAG DETECTED

- Mr. Deepak Sapra, CEO (API and Services) and Senior Management Personnel of Dr. Reddy's Laboratories Ltd., has resigned. - His resignation is effective from the close of business hours on November 12, 2026. - He is resigning to pursue opportunities outside the organization.

Governance Negative

2026-08-13 16:35

CRITICAL RED FLAG DETECTED

- Mr. Deepak Sapra has resigned from his position as CEO, API and Services and Senior Management Personnel of the company. - His resignation is effective from the close of business hours on November 12, 2026. - He is leaving to pursue opportunities outside the company.

Business Update Neutral

2026-08-07 23:31

- Dr. Reddy's terminated its agreement with Novartis India Limited (NIL), dated February 11, 2022, for distribution and promotion of select brands in India. This follows a change in NIL's controlling shareholding. The Company will commercialize the brands until September 30, 2026.

Business Update Neutral

2026-08-07 23:31

- Dr. Reddy's Laboratories terminated its agreement with Novartis India Limited (NIL) for the distribution and promotion of select brands in India. - The termination is due to a change in NIL's controlling shareholding. - Dr. Reddy's will continue commercializing these brands until September 30, 2026.

Business Update Neutral

2026-08-07 23:31

- Dr. Reddy's Laboratories terminated its distribution and promotion agreement with Novartis India Limited (NIL), originally dated February 11, 2022. - This follows a change in NIL's controlling shareholding. - Dr. Reddy's will continue commercializing the brands until September 30, 2026.

Routine Neutral

2026-08-07 23:02

New Filing detected. See link for details.

Business Update Positive

2026-08-01 09:44

- Dr. Reddy's Laboratories received U.S. FDA approval for its rituximab biosimilar on August 1, 2026. - Fresenius Kabi holds exclusive commercialization rights for the product in the United States. - The biosimilar further strengthens Dr. Reddy's global biosimilars portfolio.

Business Update Positive

2026-08-01 09:44

- Dr. Reddy's Laboratories Ltd. received U.S. FDA approval for its rituximab biosimilar on August 1, 2026. - Fresenius Kabi holds exclusive commercialization rights for the product in the United States. - This approval strengthens Dr. Reddy's global biosimilars portfolio.

Business Update Negative

2026-07-29 21:43

CRITICAL RED FLAG DETECTED

- USFDA completed a Pre-Approval Inspection (PAI) and Good Manufacturing Practices (GMP) inspection at the FTO-SEZ Process Unit-02, Srikakulam from July 20-29, 2026. - The company was issued a Form 483 with three observations, which it will address within the stipulated timeline.

Business Update Negative

2026-07-29 21:41

CRITICAL RED FLAG DETECTED

- USFDA completed a Pre-Approval and GMP inspection at Dr. Reddy's FTO-SEZ Process Unit-02, Srikakulam, from July 20-29, 2026. - A Form 483 with three observations was issued, which the company will address within the stipulated timeline.

Business Update Positive

2026-07-29 10:57

- Dr. Reddy's clarifies news regarding Thailand FDA approval for NUZOLVENCE® (zoliflodacin), an antibiotic, six months after US authorization. - The company stated this development does not constitute a material event requiring disclosure under Regulation 30.

Business Update Positive

2026-07-29 10:47

- Dr. Reddy's Laboratories clarified a news article regarding its antibiotic, NUZOLVENCE® (zoliflodacin), receiving Thai FDA approval. - The approval occurred six months after US authorization. - The company confirmed the news headline but stated there is no material impact requiring disclosure under Regulation 30.

Business Update Negative

2026-07-28 23:11

CRITICAL RED FLAG DETECTED

- Q1 FY27 consolidated revenues declined 5.6% YoY to ₹8,071 crores (US$853 million), impacted by lower lenalidomide sales and a ₹240 crore provision for semaglutide API challenges (rejected batches, lost PLI). - EBITDA margin was 12.5% (down 1416 bps YoY), primarily due to semaglutide issues and Middle East conflict; excluding this, it would be 15.4%. - Profit After Tax (PAT) for the quarter was ₹443 crores (US$47 million). - USFDA issued 7 observations during a Pre-License Inspection at a biologics manufacturing facility, which the company has responded to. - Management expects to resume semaglutide commercial supplies by November and maintains high-teens to 20% EBITDA margin guidance (excluding semaglutide impact) for the future. - Expressed confidence in a strong second half with double-digit base business growth and steady margin improvement. - Launched new complex generics including bosutinib (first-to-market with 180-day exclusivity) and nintedanib in the US.

Business Update Negative

2026-07-28 23:10

CRITICAL RED FLAG DETECTED

- Consolidated revenues declined 5.6% YoY to ₹8,071 crores (US$853 million), primarily due to lower lenalidomide sales and a ₹240 crore provision for semaglutide API related challenges. - EBITDA margin decreased to 12.5% (down 1,416 bps YoY); excluding specific provisions, it was 15.4%. PAT attributable to equity holders was ₹443 crores. - USFDA issued seven observations (Form 483) during a Pre-License Inspection at the biologics manufacturing facility, to which the company has responded. - Management is confident of a strong second half, expecting semaglutide supplies to resume by November and targeting 6-7 million pens between November and March. - The underlying base business, excluding lenalidomide, achieved healthy double-digit growth across all key geographies. - Full-year CAPEX is guided at approximately ₹1,800 crores, and R&D spend is expected to be 7-8% of revenues. Adjusted EBITDA margins are expected to be maintained in the high-teens (around 18%).

Governance Neutral

2026-07-23 21:22

- Re-appointment of Dr. K P Krishnan as an Independent Director for a second term of five years (Jan 7, 2027 - Jan 6, 2032). - Appointment of Mr. Srikanth Velamakanni as an Independent Director for five years (July 1, 2026 - June 30, 2031). - Appointment of M/s Deloitte Haskins & Sells, LLP as Statutory Auditors for five years, from the 42nd AGM to the 47th AGM.

Governance Neutral

2026-07-23 21:20

- Members at the 42nd AGM of Dr. Reddy's Laboratories Ltd. approved the re-appointment of Dr. K P Krishnan as an Independent Director for a second five-year term (Jan 7, 2027 - Jan 6, 2032). - Approved the appointment of Mr. Srikanth Velamakanni as an Independent Director for a five-year term (July 1, 2026 - June 30, 2031). - Approved the appointment of M/s Deloitte Haskins & Sells, LLP as Statutory Auditors for a five-year term.

Governance Positive

2026-07-23 21:15

- Dr. Reddy's Laboratories Ltd. held its 42nd AGM on July 23, 2026. - All resolutions were passed by the requisite majority, including the adoption of FY2025-26 financial statements and the declaration of a final dividend of ₹8/- per equity share. - Key appointments and re-appointments of directors and auditors were also approved.

Governance Neutral

2026-07-23 21:12

- Shareholders approved the re-appointment of Dr. K. P. Krishnan as an Independent Director for five years from January 7, 2027 to January 6, 2032. - Approved the appointment of Mr. Srikanth Velamakanni as an Independent Director for five years from July 1, 2026 to June 30, 2031. - Approved the appointment of M/s Deloitte Haskins & Sells, LLP as Statutory Auditors for a term of five consecutive years, commencing from the 42nd AGM.

Governance Positive

2026-07-23 21:08

- Dr. Reddy's Laboratories held its 42nd Annual General Meeting (AGM) on July 23, 2026. - Members adopted the Audited Financial Statements for the financial year ended March 31, 2026. - A final dividend of ₹8/- per equity share for FY2025-26 was declared. - Re-appointments and appointments of directors and auditors were approved. - All resolutions were passed by the requisite majority.

Governance Positive

2026-07-23 21:06

- The 42nd Annual General Meeting (AGM) of Dr. Reddy's Laboratories Limited was held on July 23, 2026. - All resolutions presented at the AGM were passed by the requisite majority. - Key resolutions passed include the adoption of financial statements for FY2026 and the declaration of a final dividend of Rs. 8/- per equity share for FY2026. - Re-appointments and appointments of directors and auditors were also approved.

Business Update Neutral

2026-07-23 08:10

- Audio recording of the Earnings call for the quarter ended June 30, 2026, conducted on July 22, 2026, has been filed by Dr. Reddy's Laboratories Ltd. A weblink to the recording is provided.

Business Update Neutral

2026-07-23 08:10

- Audio recording of the Earnings Call conducted on July 22, 2026, for the quarter ended June 30, 2026, has been made available. - Weblink provided for access.

Governance Positive

2026-07-22 16:45

- Dr. Reddy's Board Committee approved the grant of 15,933 Indian Stock Options on July 22, 2026. - Options are under the Employees Stock Option Scheme, 2018, at an exercise price of ₹1,206/- per share, vesting 100% in 3 years.

Governance Positive

2026-07-22 16:44

- Dr. Reddy's Nomination, Governance and Compensation Committee approved the grant of 15,933 stock options to eligible employees on July 22, 2026. - Options are under the Dr. Reddy's ESOP Scheme, 2018, with an exercise price of ₹1,206 per share and 100% vesting after 3 years.

Governance Neutral

2026-07-22 16:30

- Appointment of Dr. Sridevi Khambhampaty as Global Head of Biologics and Senior Management Personnel, effective July 22, 2026. - Approval of M/s Deloitte Haskins & Sells, LLP as Independent Registered Public Accounting Firm for a five-year term, subject to shareholder approval.

Financials Negative

2026-07-22 16:24

CRITICAL RED FLAG DETECTED

- Consolidated Revenue ₹8,070.5 Cr vs ₹8,545.2 Cr (▼5.6% YoY) - EBITDA ₹1,008.8 Cr vs ₹2,278.4 Cr (▼55.7% YoY) - PAT ₹443.5 Cr vs ₹1,417.8 Cr (▼68.7% YoY) - EBITDA Margin 12.5% vs 26.7% (▼1420bps) - Results include an adverse impact of ₹239.7 Cr provision related to semaglutide API issues.

Governance Positive

2026-07-22 16:23

- Board of Directors approved the appointment of Dr. Sridevi Khambhampaty as Global Head of Biologics and Senior Management Personnel, effective July 22, 2026. - M/s Deloitte Haskins & Sells, LLP was appointed as the Independent Registered Public Accounting Firm for a five-year term, commencing from the 42nd AGM, subject to shareholder approval.

Financials Negative

2026-07-22 16:19

CRITICAL RED FLAG DETECTED

- Consolidated Revenue ₹80,705 Mn vs ₹85,452 Mn (▼5.6% YoY) - EBITDA ₹10,088 Mn vs ₹22,784 Mn (▼55.7% YoY) - PAT ₹4,435 Mn vs ₹14,178 Mn (▼68.7% YoY) - EBITDA Margin 12.5% vs 26.7% (▼1420bps) - Q1FY27 results include an adverse impact of a ₹2,397 Mn provision related to semaglutide API issues. - The company received a USFDA Form 483 with seven observations for its biologics manufacturing facility.

Financials Negative

2026-07-22 16:19

CRITICAL RED FLAG DETECTED

- Consolidated Revenue ₹8,070.5 Cr vs ₹8,545.2 Cr (▼6% YoY) - EBITDA ₹1,008.8 Cr vs ₹2,278.4 Cr (▼56% YoY) - PAT ₹443.5 Cr vs ₹1,417.8 Cr (▼69% YoY) - EBITDA Margin 12.5% vs 26.7% (▼1420bps) - Key impacts include a ₹239.7 Cr provision for semaglutide API issues, reduced Lenalidomide sales, price erosion in North America/Europe Generics, and elevated solvent costs.

Business Update Negative

2026-07-15 16:26

CRITICAL RED FLAG DETECTED

- Dr. Reddy's Laboratories reported a manufacturing issue with Semaglutide injection where an impurity was found out of specification in scale-up batches, causing degradation in the finished drug product. - This has led to a temporary halt in commercial supplies, with resumption expected late October/early November 2026 after process adjustments and re-validation. - The company now anticipates supplying 6-7 million pens between Q3 and Q4 FY27, which is a reduction from the earlier annual target of 12 million pens for the first year of launch. - No patient safety impact on products already supplied to the market; no recall is necessary. There may be a need to write down affected inventory, but no penalties are anticipated from partners.

Business Update Negative

2026-07-15 16:24

CRITICAL RED FLAG DETECTED

- Dr. Reddy's reported a temporary halt in commercial supplies of Semaglutide injection due to an impurity detected in scale-up batches of the API, causing the finished drug product to be out of specifications. - The company expects to resume commercial supply around late October/early November 2026, following process adjustments and re-validation, which are anticipated to take until the end of September. - The updated outlook for Semaglutide pen supply for FY27 is 6-7 million pens between Q3 and Q4, in addition to prior sales, a reduction from the previously guided 12 million pens. - There is no impact on patient safety, existing global regulatory filings, or the supply of Semaglutide oral tablets. - The issue may lead to a write-down of associated inventory and will be a downside to previous revenue expectations, though the long-term EBITDA margin target (20%+) remains unchanged.

Business Update Neutral

2026-07-13 14:37

- Concall Schedule - Concall Date: July 22nd, 2026 - Concall Time: 19:30 PM IST / 10:00 AM ET

Business Update Neutral

2026-07-13 14:36

- Concall Schedule - Concall Date: Wednesday, July 22nd, 2026 - Concall Time: 19:30 PM IST / 10:00 AM ET

Business Update Neutral

2026-07-10 08:53

- Audio recording of the conference call conducted on July 9, 2026, has been made available. - The weblink for the recording is provided for information and records.

Business Update Neutral

2026-07-10 08:47

- Audio recording of the conference call conducted on July 9, 2026, is now available. Weblink provided for access.

Business Update Negative

2026-07-09 09:39

CRITICAL RED FLAG DETECTED

- Dr. Reddy's reported that certain batches of semaglutide were found to be out of specification due to API issues, causing commercial supply delays. No impact on patient safety or regulatory filings. - Concall Schedule - Concall Date: Thursday, July 9, 2026 - Concall Time: 16:30 – 17:00 IST | 07:00 – 07:30 ET

Business Update Negative

2026-07-09 09:37

- Dr. Reddy's reported that certain batches of semaglutide API were found out of specification, leading to delayed commercial supplies of the product. The company stated no impact on patient safety or existing global regulatory filings. - A conference call to discuss this issue is scheduled for Thursday, July 9, 2026, from 16:30 – 17:00 IST.

Business Update Negative

2026-07-09 09:20

CRITICAL RED FLAG DETECTED

- Dr. Reddy's Laboratories reports certain batches of semaglutide were found out of specification due to an API issue, leading to delayed commercial supplies for a certain period of time. No impact on patient safety or global regulatory filings. - The company will host a conference call to discuss this topic. - Concall Date: Thursday, July 9, 2026 - Concall Time: 16:30 – 17:00 IST | 07:00 – 07:30 ET

Business Update Negative

2026-07-09 09:17

CRITICAL RED FLAG DETECTED

- Dr. Reddy's announced certain batches of semaglutide were out of specification due to an API issue, causing delayed commercial supplies. No impact on patient safety or global regulatory filings. A conference call to discuss this issue is scheduled for July 9, 2026, 16:30 – 17:00 IST.

Governance Positive

2026-06-30 20:02

- The 42nd Annual General Meeting (AGM) will be held on Thursday, July 23, 2026, at 11:00 a.m. via Video Conferencing/OAVM. - The Board recommended a final dividend of ₹8 per equity share for FY 2025-26. - The record date for the dividend is Friday, July 10, 2026, with payment on or before July 30, 2026.

Governance Positive

2026-06-30 19:58

- The 42nd Annual General Meeting (AGM) will be held on Thursday, July 23, 2026, at 11:00 a.m. via Video Conferencing/Other Audio Visual Means. - A final dividend of ₹8 per equity share for FY 2025-26 has been declared, with a record date of July 10, 2026. - E-voting for the AGM will be available from July 19, 2026, to July 22, 2026.

Governance Negative

2026-06-30 19:43

- Dr. Reddy's Laboratories Ltd. submitted its Integrated Annual Report, Business Responsibility and Sustainability Report, and the Notice of the 42nd Annual General Meeting for the financial year 2025-26. The submission complies with SEBI Listing Regulations.

Business Update Positive

2026-06-30 19:37

- The company filed its Business Responsibility & Sustainability Report for FY2025-26. - Report highlights include 98% global waste diversion and a 50% absolute reduction in Scope 1&2 emissions from the 2023 baseline. - No reported disciplinary actions for bribery/corruption or regulatory fines.

Governance Positive

2026-06-30 19:33

- Notice of 42nd Annual General Meeting (AGM) to be held on Thursday, July 23, 2026, at 11:00 a.m. IST via Video Conferencing. - The Board recommended a final dividend of ₹8 per equity share for the financial year ended March 31, 2026. - Key agenda includes adoption of financial statements, re-appointment of directors, appointment of new independent director, and appointment of statutory auditors. - The cut-off date for e-voting is Thursday, July 16, 2026.

Business Update Positive

2026-06-30 19:29

- Filed Business Responsibility & Sustainability Report (BRSR) for FY2025-26. - Highlights include 80.1% employee ethical conduct training, 98% global waste diverted from landfill, and 78% electricity from renewable power. - The company reported a 50% absolute reduction in Scope 1&2 emissions from baseline year 2023 and aims to serve 1.5 billion patients by 2030.

Governance Positive

2026-06-30 19:24

- Notice of 42nd Annual General Meeting to be held on Thursday, July 23, 2026, at 11:00 A.M. IST via video conference. - Agenda includes adoption of financial statements for FY26, declaration of a final dividend of ₹8/- per equity share, re-appointment of directors, and appointment of Deloitte Haskins & Sells LLP as statutory auditors. - The cut-off date for e-voting is July 16, 2026, with voting from July 19-22, 2026. - Final dividend, if declared, will be paid on or before July 30, 2026.

DRREDDY

Dr Reddys Laboratories Ltd

Price Chart

Filing History

Unlock Full History